(Q43649705)

25 November 2017

Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss (English)

1 reference

25 November 2017

0 references

Trouillot TE

1

1 reference

25 November 2017

Pace DG

2

1 reference

25 November 2017

McKinley C

3

1 reference

25 November 2017

Cockey L

4

1 reference

25 November 2017

Zhi J

5

1 reference

25 November 2017

Häeussler J

6

1 reference

25 November 2017

Guerciolini R

7

1 reference

25 November 2017

Showalter R

8

1 reference

25 November 2017

Everson GT

9

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

The American Journal of Gastroenterology

25 November 2017

1 reference

25 November 2017

96

1 reference

25 November 2017

6

1 reference

25 November 2017

1888-1894

1 reference

Gallstone formation during weight-reduction dieting

25 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03783.X

Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03783.X

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03783.X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03783.X

10.1111/J.1572-0241.2001.03783.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference